A Uniform Procedure for Reimbursing the Off-Label Use of Antineoplastic Drugs According to the Value-for-Money Approach

REFERENCES

• Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA. 2005; 294 (20): 2618–22.
   PubMed Web of Science ®Google Scholar
• Folino-Gallo P, Montilla S, Bruzzone M, Martini N. Pricing and reim-bursement of pharmaceuticals in Italy. Eur J Health Econ. 2008 Aug ; 9 (3): 305–10.
   PubMed Web of Science ®Google Scholar
• Garber AM, McClellan MB. Satisfaction Guaranteed-payment by Re-sults for Biologic Agents. N Engl J Med 2007; 357 (16): 1575–7.
   PubMed Web of Science ®Google Scholar
• Towse A. Should NICE& threshold range for cost per QALY be raised? Yes. BMJ. 2009 Jan 26; 338: b181.
   Google Scholar
• Towse A. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong? Br J Clin Pharmacol. 2010; 70: 360–6
   Google Scholar
• Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008 Feb 2; 336 (7638): 251–4
   PubMed Web of Science ®Google Scholar
• Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Threshold values for cost-effectiveness in health care Health Technology Assessment (HTA). Brus-sels: Belgian Health Care Knowledge Centre (KCE); 2008. KCE reports 100C (D/2008/10.273/96)
   Google Scholar
• Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer. 2009 May; 45 (8): 1397–406.
   PubMed Web of Science ®Google Scholar
• Lucioni C, Mazzi S, Polcaro F. 11 Risk Sharing come applicazione del Value Based Pricing. PharmacoEconomics - Italian Research Articles 2010; 12: 71–80.
   Google Scholar
• McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness thresh- old: what it is and what that means. Pharmacoeconomics. 2008; 26 (9): 733–44.
   PubMed Web of Science ®Google Scholar
• Trippoli S, Santarlasci B, Messori A, Scroccaro G. L'analisi costo-efficacia come strumento per la definizione del prezzo dei prodotti innovativi: cenni metodologici ed esempio di applicazione ai dispositivi medici. Gior-nale Italian° di Farmacia Clinica 2006; 20: 383–7.
   Google Scholar
• Richardson DL, Backes FJ, Seamon LG, Zanagnolo V, O'Mailey DM, Cohn DE, et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008; 111 (3): 461–6.
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-707.
   Google Scholar
• Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol. 1989; 7 (1): 36–7.
   PubMed Web of Science ®Google Scholar
• Jang RW, Le Maitre A, Ding K, Winton T, Bezjak A, Seymour L, et al. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol. 2009; 27: 4268-73
   Google Scholar
• Marcus R, Aultman R, Jost F. A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of ad-vanced follicular non-Hodgkin's lymphoma. Br J Cancer. 2010; 102 (1): 19–22.
   PubMed Web of Science ®Google Scholar
• Zbrozek AS, Hudes G, Levy D, Strahs A, Berkenblit A, DeMarinis R, Parasuraman S. Q-TWiST analysis of patients receiving temsirolimus or in-terferon alpha for treatment of advanced renal cell carcinoma. Pharma-coeconomics. 2010; 28 (7): 577–84.
   PubMed Web of Science ®Google Scholar
• Messori A, Trippoli S, Bonacchi M, Sani G. Left-ventricular assist de-vice as destination therapy: application of the payment-by-results approach for the device reimbursement. J Thorac Cardiovasc Surg 2009; 138 (2): 480–5.
   PubMed Web of Science ®Google Scholar
• Regione Toscana, document available at: www.us15.toscana.it/im-ages/stories/farma/a1la394.pdf accessed on 17 May 2010.
   Google Scholar
• AIFA, Agenzia Italiana sul Farmaco, document available at www.anti-neoplasticlagenziafarmaco.ft/info_generali.htm accessed on 21 September 2010.
   Google Scholar
• NICE, National Institute For Health And Clinical Excellence. Final ap-praisal determination - Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer. Document available at: http ://www.nice. org .uk/nicemedia/live/12185/48834/48834.pdf
   Google Scholar
• Stone R, Sekeres M, Garcia-Manero G, Lyons RM. Recent advances in low- and intermediate-l-risk myelodysplastic syndrome: developing a con-sensus for optimal therapy. Clin Adv Hematol Oncol. 2008; 6 (12): 1–15.
   PubMedGoogle Scholar
• Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA; Cancer and Leukemia Group B. Further analy-sis of trials with azacitidine in patients with myelodysplastic syndrome: stud-ies 8421, 8921, and 9221 by the Cancer and Leukemia Group Br J Clin Oncol. 2006; 24 (24): 3895-903.
   Google Scholar
• Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361 (10): 947–57.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, ritux-imab, and cyclophosphamide. J Clin Oncol 2007; 25 (22): 3344–9.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Greipp PR, Gertz MA, et al. Waldenström's macroglobuli-naemia: a prospective study comparing daily with intermittent oral chlo-rambucil. Br J Haematol 2000; 108 (4): 737–42.
   PubMed Web of Science ®Google Scholar
• Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost ef-fectiveness: a case study in the challenges associated with 21st-century Cancer drug pricing. J Clin Oncol 2009; 27 (13): 2111–3.
   PubMed Web of Science ®Google Scholar
• Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol 2009; 27 (35): 5868–73.
   PubMed Web of Science ®Google Scholar